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Background: Recent work suggests that ALS and frontotemporal dementia can occur together and share at least
in part the same underlying pathophysiology. However, it is unclear at present whether memory deficits in ALS
stem from a temporal lobe dysfunction, or are rather driven by frontal executive dysfunction. In this study we
sought to investigate the nature of memory deficits by analyzing the neuropsychological performance of 40 ALS
patients in comparison to 39 amnestic mild cognitive impairment (aMCI) patients and 40 healthy controls (HC). The
neuropsychological battery tested for impairment in executive functions, as well as memory and visuo-spatial skills,
the results of which were compared across study groups. In addition, we calculated composite scores for memory
(learning, recall, recognition) and executive functions (verbal fluency, cognitive flexibility, working memory). We
hypothesized that the nature of memory impairment in ALS will be different from those exhibited by aMCI patients.
Results: Patient groups exhibited significant differences in their type of memory deficit, with the ALS group showing
impairment only in recognition, whereas aMCI patients showed short and delayed recall performance deficits as well as
reduced short-term capacity. Regression analysis revealed a significant impact of executive function on memory
performance exclusively for the ALS group, accounting for one fifth of their memory performance. Interestingly,
merging all sub scores into a single memory and an executive function score obscured these differences.
Conclusion: The presented results indicate that the interpretation of neuropsychological scores needs to take the
distinct cognitive profiles in ALS and aMCI into consideration. Importantly, the observed memory deficits in ALS were
distinctly different from those observed in aMCI and can be explained only to some extent in the context of comorbid
(coexisting) executive dysfunction. These findings highlight the qualitative differences in temporal lobe dysfunction
between ALS and aMCI patients, and support temporal lobe dysfunction as a mechanism underlying the distinct
cognitive impairments observed in ALS.
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Amyotrophic lateral sclerosis (ALS) is a progressive neu-
rodegenerative disorder, characterized by hallmark motor
neuron and corticospinal tract degeneration. It is well-
established that ALS shares clinical [1], pathological [2]
and genetic [3] characteristics with frontotemporal de-
mentia (FTD), and this overlap has led some studies to as-
sert the existence of a single continuum on which both
ALS and FTD lie [4,5]. Recent studies indicate a global
neuropsychological deficit wherein impairment of execu-
tive functions is reported the most [6-14]. However, there
is increasing evidence that other cognitive domains such as
language and memory are also affected [7,10,15-19]. Espe-
cially memory impairment has been somewhat neglected
and often seen as a failure of encoding as an executive
component of memory [8,17,20]. However, there are re-
ports on memory dysfunction in ALS, often tested with pic-
ture recall, word list learning, pair association learning or
story recall [12,14,18,21-30]. Most of them support an en-
coding or short recall deficit with relatively sparing of con-
solidation performance but the findings are inconsistent
and have not been related to temporal lobe dysfunction.
Recently, there has been growing postmortem and in vivo
evidence of temporal lobe involvement in ALS, based on
hippocampal TDP-43 pathology [31,32] and volume loss
[33-35]. Temporal lobe pathology is also a key feature of
Alzheimer's Disease (AD) with hippocampal atrophy even
in early stages [36]. Based on the shared hippocampal in-
volvement in both ALS and AD, we sought to investigate
whether there are distinctive differences between the sort
of memory deficits in ALS and AD. However, the extent of
hippocampal pathology in AD is, up to current knowledge,
far more progressed and widespread than in ALS making a
direct comparison between ALS and AD patients very diffi-
cult if not impossible. Therefore we decided to compare
ALS patients to a group of patients that suffer from an AD
prodromal stage, amnestic mild cognitive impairment
(aMCI) [37]. Patients with aMCI have overt deficits in cog-
nition, especially in the memory domain, but are still largely
independent in daily activities. They have a far higher risk
of developing dementia than cognitively normal persons,
but at the individual patient level the prognosis might be
variable [38]. The temporal lobe pathology as hippocampal
atrophy is also a hallmark in aMCI but it occurs to a much
smaller extent than in AD [39]. Therefore this group of pa-
tients is comparable to patients with ALS in terms of hip-
pocampal degeneration. In the current work we focussed
on verbal memory performance and hypothesized a qualita-
tive difference between patients with ALS and aMCI.
Methods
Subjects
40 ALS patients were recruited from the outpatient clinics
of the Departments of Neurology at the Otto-von-Guericke University of Magdeburg and Hannover Medical
School between 04/2011 and 03/2012. ALS patients were
diagnosed according to the revised El Escorial Criteria
[40], and the Amyotrophic Lateral Sclerosis Functional
Rating Scale - Revised (ALSFRS-R, [41]) was used to
evaluate their functional status. Three ALS patients ful-
filled the Rascovsky criteria for behavioural variant fronto-
temporal dementia (ALS-FTD, [42]), and were included in
the analysis to represent the full spectrum of cognitive im-
pairment in ALS. ALS Patients with a history of other
neurological conditions that could affect cognition (major
hemispheric stroke, traumatic brain injury), severe active
mental illness, or alcohol abuse were excluded.
In addition, 39 aMCI patients were recruited from the
memory outpatient clinic in Magdeburg and classified
according to the revised Peterson Criteria for mild cog-
nitive impairment [37]. A group of 40 healthy age- and
gender- matched controls without a prior history of
neurological or psychiatric illness was also recruited. In
the healthy control group, only subjects who performed
within the normal range of the Montreal Cognitive As-
sessment (MoCA; cut-off 26/30) were included. The
local ethics committee of Otto-von-Guericke University
approved the study and all participants gave their writ-
ten informed consent prior to their inclusion.
Neuropsychological assessment and data analysis
All participants underwent a detailed neuropsychological
assessment in conjunction with their clinical examination.
The battery of tests included a range of standardized
neuropsychological instruments and was designed based
on the ALS literature suggesting an early decline of
frontally-mediated executive functions in ALS patients
[6-8,10]. To assess the executive domain, the Regensbur-
ger verbal fluency test [43] was used to survey phonemic
verbal fluency (letter “K”) and flexibility (alteration be-
tween letters “G” and “R”). Additionally, we tested for cog-
nitive flexibility with the Trail Making Test (the ratio
between part B and A was computed to account for motor
impairment) [44] and for verbal working memory per-
formance (Wechsler Memory scale-revised (WMS-R),
digit span backwards) [45]. The battery also tested for im-
pairment in non-executive cognitive domains. To assess
memory functions, the German version of the Rey Audi-
tory Verbal Learning Test (RAVLT) [46], and the forward
digit span task from the revised Wechsler Memory Scale
[45] was used. Visuo-spatial abilities were evaluated using
the Rey Complex Figure Test (RCFT) [47]. Mood was
assessed using Beck Depression Inventory-II [48]. Neuro-
psychological performance between the study groups was
compared by one-way analysis of variance (ANOVA) with
group as a main factor (ALS/aMCI/HC). Because of some
physical disabilities in the ALS cohort, not all patients
completed all tests. The missing data strategy was to
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retained in the dataset. All tests were two-tailed and the
statistical significance threshold was set at p < 0.05.
Bonferroni correction was applied to adjust the α-value
for post hoc analysis where applicable.
To determine whether the patient groups could be dif-
ferentiated based on group level with less refined neuro-
psychological measures, we computed composite scores
for “Memory” and “Executive function” by transforming
the raw values into Z-scores that were referenced by
mean and standard deviation of the healthy controls on
the corresponding test. Composite “Memory” scores in-
corporated the following parameters: learning (sum of
trials 1–5 of the RAVLT), immediate verbal recall (differ-
ence between trial 5 and trial 6), delayed verbal recall
(difference between trial 5 and trial 7) and recognition
(corrected for false positive and interference items). “Ex-
ecutive function” score included measures of verbal flu-
ency, cognitive flexibility and verbal working memory.
These scores were compared across patient groups
(ALS/aMCI) using t-tests for non-dependent samples,
but also used to conduct a regression analysis to esti-
mate the influence of executive function on memory
performance in each of the three groups.
All statistical analyses were carried out using SPSS for
Windows, Version 21.0 (IBM SPSS Statistics, Armonk,
NY, USA; RRID:rid_000042).
Results
Demographic and clinical characteristics
Demographic and clinical data are summarized in
Table 1. An analysis of variance indicated no difference
in age (F2,116 = 1.92, p = 0.15) and a trend in gender dis-
tribution (Χ2 = 5.53, p = 0.06). There was also a trend to-
ward higher self-reported depression scores in ALS
patients (F2,103 = 2.94, p = 0.06). However, none of the
three groups scored within the range of clinically rele-
vant depressive symptoms (Beck Depression Inventory-II
<13 points). There was a difference between groups re-
garding their completed educational years (F2,114 = 4.28,Table 1 Baseline characteristics
Demographic variable ALS N
Age at time of assessment 60.4 (12.2) 40
Male sex 65.0% (−) 40
Education (years)* 13.0 (2.5) 40
BDI-II (estimated depression scores) 7.9 (6.6) 34
ALSFRS-R 38.4 (7.8) 40
Disease duration (in months; from symptom onset) 22.16 (19.5) 40
Disease progression 0.54 (0.36) 40
Values are mean (SD). Two-tailed p-values of <0.05 are considered significant, show
ALS, amyotrophic lateral sclerosis; MCI, mild cognitive impairment; BDI-II, Beck Depr
applicable; disease duration, time from symptom onset to assessment; disease progres
since symptom onset (48-ALSFRS-R/disease duration [38]); *Years of education includep = 0.02). Patients with ALS (13.0 ± 2.5) have less educa-
tional years than aMCI (14.6 ± 2.8), but both patient
groups did not differ from healthy controls (14.0 ± 2.1).
Neuropsychological performance of ALS, aMCI patients,
and control subjects
A significant group effect was identified in the memory
domain for the following variables: Digit span (F2,114 =
8.58, p < 0.001), immediate verbal recall (F2,115 = 5.91, p =
0.004), delayed verbal recall (F2,115 = 6.97, p = 0.001) and
recognition (F2,116 = 3.69, p = 0.028). Significant group ef-
fects were also revealed for tests of executive function:
Phonemic fluency (F2,112 = 11.00, p < 0.001) and flexibility
(F2,112 = 18.47, p < 0.001) and working memory perform-
ance (F2,114 = 10.48, p < 0.001). Visuo-spatial performance
was also significantly different between the three groups
(F2,104 = 6.42, p = 0.002). No differences were observed for
verbal learning (F2,116 = 2.67, p = 0.074). Mean values and
standard deviations for neuropsychological subtests are
presented in Table 2. Figure 1 illustrates the percentage of
aMCI patients and ALS patients that fell more than 1.5
standard deviations below the performance of healthy
controls in each neuropsychological subtests.
The analysis of composite scores for each cognitive
domain revealed no main effect for overall “Memory”
and “Executive function”. Within-group comparisons in
the form of regression analysis revealed no significant
impact of “Executive function” on “Memory” for neither
the aMCI group (r = 0.25, p = 0.13) nor the healthy con-
trol group (r = −0.02, p = 0.88). In ALS patients there
was a significant relationship between the two domains
(r = 0.45, p = 0.003) with “Executive function” accounting
for 20.5% of the variance in “Memory” performance.
Discussion
This cross-sectional study of neuropsychological per-
formance in controls, ALS and aMCI patients revealed a
significant deficit in verbal memory function in both pa-
tient groups relative to controls. In patients with ALS
we observed additional dominant executive deficitsAmnestic MCI N Healthy controls N p-value
64.5 (5.4) 39 62.7 (10.2) 40 0.152
45.0% (−) 39 69.2% (−) 40 0.063
14.6 (2.8) 37 14.0 (2.1) 40 0.016





ession Inventory-II; ALSFRS-R, ALS Functional Rating Scale Revised; n.a., not
sion, estimated using decline in ALS Functional Rating Scale (ALSFRS-R) score
: Years attended in school plus years of the longest, completed education.
Table 2 Post-hoc test results in neuropsychological tests for patients and controls: raw scores and p - values







Phonemic fluency* 10.9 (4.5) 40 12.4 (4.1) 35 15.2 (4.0) 40 <0.001 0.011 0.39
Phonemic flexibility* 9.0 (3.3) 40 10.7 (3.5) 35 13.3 (2.9) 40 <0.001 0.002 0.08
Digit span backward raw score* 5.5 (1.5) 38 4.6 (1.2) 39 6.1 (1.4) 40 0.26 <0.001 0.02
Cognitive flexibility (TMT ratio) 2.8 (1.0) 34 2.6 (1.0) 38 2.5 (1.4) 40 0.62 1.00 1.00
Memory
RAVLT Learning (∑1-5) 44.3 (10.5) 40 42.6 (8.2) 39 47.3 (9.0) 40 0.43 0.07 1.00
RAVLT Immediate recall (5–6)* 2.6 (1.7) 39 3.2 (1.8) 39 1.9 (1.7) 40 0.19 0.003 0.37
RAVLT Delayed recall 20’-30’ (5–7)* 2.7 (1.8) 40 3.7 (2.2) 39 2.0 (2.2) 39 0.41 0.001 0.08
RAVLT Recognition (W–F)* 9.1 (5.9) 40 9.4 (4.9) 39 11.8 (3.4) 40 0.04 0.09 1.00
Digit span forward raw score* 7.2 (1.5) 38 6.3 (1.3) 39 7.6 (1.5) 40 0.90 <0.001 0.01
Visuospatial functions
RCFT* 31.0 (3.8) 34 33.4 (2.6) 33 33.1 (2.6) 40 0.01 1.00 0.005
Values are mean (SD). Two-tailed p values of <0.05 are considered significant, shown in bold.
ALS, Amyotrophic Lateral Sclerosis; aMCI, amnestic mild cognitive impairment; HC, healthy controls; RCFT, Rey Complex Figure Test; *significant on one-way ANOVA.
Machts et al. BMC Neuroscience 2014, 15:83 Page 4 of 7
http://www.biomedcentral.com/1471-2202/15/83including the impairment of verbal fluency, which is a
consistent, well-documented finding in motor neuron
disease [7,8,11,14]. This deficit also has an impact on
disease progression [6] and survival [49]. In contrast, re-
ports on memory dysfunction are more inconsistent.
When evaluating overall memory impairment as a com-
posite parameter of several memory subdomains, there
were no differences between aMCI and ALS patients.
However, examining the nature of amnestic deficits based
on more predefined sub-functions revealed disease-group
specific patterns of impairment. Patients with aMCI had
overt deficits in short and delayed recall, whereas ALS pa-
tients were mainly impaired in verbal memory recogni-
tion. Recall deficits in aMCI are a hallmark feature of this
patient group and support the notion of being a pre-Figure 1 Neuropsychological profile of patients with ALS and aMCI. P
<1.5 SD below the mean of healthy controls for subtests within each cognAlzheimer's Disease stage [37]. Recall performance in pa-
tients with ALS was not affected. Previous studies, that
took verbal memory into account, have reported both, im-
paired and preserved recall performance on word-list
learning tests, depicting the inconsistency among ob-
served memory deficits in ALS. One study reported long-
delay recall impairment but no impairment on short-term
recall or recognition [23], while others report deficits in
short recall performance but preserved delayed recall per-
formance [12], or impairment in both, short and delayed
recall [18]. Based on the high variability regarding cogni-
tive deficits between patients, recent population-based
studies propose a neuropsychological classification into
subgroups with focus on executive impairment or non-
executive impairment [7] and a novel screening tool hasrofile lines display the percentage of ALS patients and aMCI patients
itive domain.
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[15]. However, given the results yielded in the present
study, memory deficits in ALS seem to be disease specific
and can be differentiated from other neurodegenerative
diseases such as AD when assessed specifically. Recogni-
tion deficits in patients with ALS were found the most ob-
vious memory deficit and have been reported before
[17,50], although such deficits have been mostly associated
with executive dysfunction [17,29]. In our cohort, execu-
tive impairment could only account for 20.5% of memory
performance in ALS, which supports the emerging notion
that executive function is only one of several cognitive do-
mains impaired in ALS [7,16]. Moreover, executive dys-
function in frontotemporal dementia has been related to
failure in source memory but not recognition performance
[51], which leads to the assumption that the recognition
deficit reported here cannot be caused solely by executive
dysfunction. Impairment in recognition can emerge from
either insufficient encoding as a temporal lobe function or
from deficient prefrontal cortical function. However, both
assumptions would lead to a higher amount of errors and
interference biases, which was more pronounced in
patients with ALS than with aMCI. In experimental
psychology, recognition memory is understand as a ‘dual-
process’ model that incorporates the product of two differ-
ent memory functions, namely familiarity and recollection
[52]. Thus, recognition judgements can be based on the
recollection of details about previous events or on the as-
sessment of stimulus familiarity [53]. In ALS, only one
study so far investigated recognition memory and its
underlying neuronal mechanisms [50]. The paradigm con-
sisted of a verbal recognition task, where the subjects had
to decide whether a word was presented before or not. Al-
though this was an experimental set up, results can be
compared to the recognition test that was used in this
study (RAVLT). Similar to our observations, Muente et al.
[50] reported a recognition deficit in patients with ALS
that was related to an absent recognition associated event-
related potential. Interestingly, this effect was not observed
in patients with Alzheimer's Disease which completed a
comparable task [54]. These results support the different
qualities of memory impairment in ALS and AD observed
in the current study.
In addition to detailed neuropsychological testing and/
or neurophysiological measures, imaging studies could
provide more information about the specific anatomical
structures involved. A number of studies correlated cog-
nitive performance with white or grey matter integrity
[4,30,55,56], but only two focused on word list learning
and structural integrity. The results however seem in-
consistent since one reported a relationship between
memory performance in ALS and uncinate fasciculus
(UF) integrity [30], whereas the other study found no
such association [55]. Since both studies had relativelysmall sample sizes, further structural-functional correla-
tions are needed to draw more definite conclusions on
the relationship between memory impairment and cere-
bral pathology in ALS. Given that the uncinate fasciculus
connects temporal lobe structures such as the hippo-
campus with frontal lobe areas, its involvement high-
lights the contribution of structures other than the
frontal lobe in memory performance in ALS. Hippocam-
pal and parahippocampal pathology in ALS are well-
described in post mortem studies [32,34,35], and lesions
have been related to memory deficits. Interestingly, those
lesions were different from those found in Alzheimer's
Disease [34], which underlines the distinct neuropsycho-
logical profiles between patients with ALS and aMCI in
the present study. There is further evidence from struc-
tural imaging, that the hippocampus, a key structure in
memory function, is affected in ALS. Both hippocampal
volume reduction [33] and parahippocampal surface al-
terations [57,58] are sites of ALS pathology, but these
changes have not been related in-vivo to patients’ mem-
ory performance to date. Overall, imaging data support
the notion that memory impairment in ALS is not
caused exclusively by executive dysfunction. Further re-
search needs to establish the relationship of temporal
lobe involvement and memory impairment in ALS.
This study measured a wide range of cognitive do-
mains, including verbal memory, executive functions
and visuo-spatial skills with standardized neuropsycho-
logical tests. Tests of verbal memory revealed substantial
recognition deficits in patients with ALS. However, there
are some limitations to take into account. Initially we
did not have a specific hypothesis which sub-function of
memory would differ between ALS and aMCI and there-
fore chose a memory test that covers several sub-
functions (RAVLT). With the results presented here,
further research should focus on recognition memory,
both verbal and visual, and investigate if the observed
deficits are caused by deficient familiarity or recollection
performance. It would be of interest to relate it to pre-
frontal lobe dysfunction as well, either measured by be-
havioural or imaging parameters in order to identify
correlates of impaired recognition in ALS.
Conclusions
In conclusion, the current investigation suggests that
memory impairment in ALS is different from that ob-
served in Alzheimer's disease, but also that there is con-
siderable overlap in verbal memory performance between
these conditions. The differentiation between the distinct
cognitive profiles of the two patient groups can only be
captured with detailed subdomain specific neuropsycho-
logical testing, and composite scores of domain level per-
formance proved insufficient. Moreover, this study further
underscores on the considerable extramotor deficits in
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Emerging cognitive screening tests in ALS, which are in-
creasingly used in clinical trials and specialist clinics
should take the unique memory deficits of ALS into con-
sideration. The pragmatic implications of memory impair-
ment in ALS in relation to compliance with medications
and assistive devices are currently also understudied. At
present there is a growing consensus that cognitive im-
pairment in ALS is not solely dominated by executive dys-
function, but language and amnestic deficits are equally
important.
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